Inflammasomes and Cancer
Rajendra Karki, Si Ming Man, and Thirumala-Devi Kanneganti

Abstract

Inflammation affects all stages of tumorigenesis. A key signaling pathway leading to acute and chronic inflammation is through activation of the caspase-1 inflammasome. Inflammasome complexes are assembled on activation of certain nucleotide-binding domain, leucine-rich repeat–containing proteins (NLR), AIM2-like receptors, or pyrin. Of these, NLRP1, NLRP3, NLRC4, NLRP6, and AIM2 influence the pathogenesis of cancer by modulating innate and adaptive immune responses, cell death, proliferation, and/or the gut microbiota. Activation of the inflammasome and IL18 signaling pathways is largely protective in colitis-associated colorectal cancer, whereas excessive inflammation driven by the inflammasome or the IL1 signaling pathways promotes breast cancer, fibrosarcoma, gastric carcinoma, and lung metastasis in a context-dependent manner. The clinical relevance of inflammasomes in multiple forms of cancer highlights their therapeutic promise as molecular targets. In this review, we explore the crosstalk between inflammasomes and the development of various tumors and discuss possible therapeutic values in targeting the inflammasome for the prevention and treatment of cancer.

Introduction

Inflammation triggered by microbial or danger signals drives many forms of cancer in humans (1). Inflammation associated with tumor development is triggered by a variety of immune cells, including macrophages, neutrophils, dendritic cells, natural killer (NK) cells, and T and B lymphocytes (2). A central mechanism driving inflammation in immune cells is orchestrated by the inflammasome, a cytoplasmic multimeric protein complex that provides a molecular platform for activation of the cysteine protease caspase-1 (3). Activated caspase-1 mediates proteolytic cleavage and release of the proinflammatory cytokines IL1β and IL18 and initiates an inflammatory form of programmed cell death known as pyroptosis (3).

Certain members of the nucleotide-binding domain, leucine-rich repeat containing proteins (NLR) and AIM2-like receptors (ALR), form inflammasome complexes in response to pathogen-associated molecular patterns (PAMP) or danger-associated molecular patterns (DAMP; ref. 3). Mutations in genes encoding inflammasome components often lead to susceptibilities to cancer, infection, and autoimmune diseases in humans. In the context of cancer, polymorphisms in the gene encoding NLRP1 are linked to mesothelioma (4), melanoma (5), and epidermal hyperplasia (6); those of NLRP3 are associated with melanoma (5) and colorectal cancer (7); and those of AIM2 with colorectal cancer (8). Furthermore, our contemporary appreciation of the functional importance of inflammasomes in cancer is illuminated by mouse models. Here, we highlight recent development in our understanding of inflammasomes in cancer and outline the therapeutic potential of modulating inflammasome responses for use in anticancer therapies.

Protective Roles of Inflammasomes in Cancer

The global inflammasome-initiating sensor of PAMPs and DAMPs, NLRP3, assembles a fully functional inflammasome complex by recruiting the inflammasome adaptor protein, ASC, and the cysteine protease, caspase-1. The ability of NLRP3 to respond to a variety of signals contributes to its biological importance in a number of diseases, including colorectal cancer, melanoma, and transplantable tumors. Multiple studies have shown that mice lacking NLRP3 are hypersusceptible to colitis and colitis-associated colorectal cancer induced by the DNA damaging agent azoxymethane (AOM) and chemical colitogen dextran sulfate sodium (DSS; refs. 9–12). However, another study has suggested that mice lacking NLRP3 are more resistant to DSS-induced colitis compared with wild-type mice (13), whereas a further study has found a similar tumor burden between wild-type mice and mice lacking NLRP3, treated with AOM and DSS (14). It is possible that alteration in the gut microbiota between different animal facilities could have contributed to the differences observed in these studies. It is important to note that mice lacking ASC and caspase-1 are also susceptible to DSS-induced colitis and colitis-associated colorectal cancer (9–11, 15), providing substantial evidence to favor a protective role of inflammasomes in an inflammatory model of colorectal cancer.

Bone marrow chimera studies have identified that signaling through the NLRP3 inflammasome in the hematopoietic, but not in the stromal, compartment is essential for mediating protection against tumorigenesis (9, 10). The ability of inflammasome sensors such as NLRP3 to mediate secretion of IL18, a cytokine that contributes to epithelial barrier repair against damage, is a potential mechanism explaining the protective role of IL18 against colitis-associated colorectal cancer (Fig. 1A; refs. 5, 6, 11–15).
cells and promotes in
endothelial growth factor A (VEGFA) and accelerates the progression of breast cancer. In some cases, ASC increases the viability and growth of melanoma
NK cells and increases lung metastasis in certain models of melanoma. The NLRC4 in
IL1 signaling drives accumulation of MDSCs and promotes primary and metastatic mammary tumors. In
chemotherapeutic agents in thymoma. Overexpression of IL1
protein (IL22BP), and inhibit the colonization of colitogenic microbiota, possibly through its role in MUC2 secretion by goblet cells. The NLRP3 in
colitis-associated colorectal cancer. The IL18 axis can also induce tumoricidal activity of NK cells against metastasized colonic tumor cells, downregulate IL22 binding
protein (IL22BP), and inhibit the colonization of colitogenic microbiota, possibly through its role in MUC2 secretion by goblet cells. The NLRP3 inflammasome
and the IL1β–IL1 receptor (IL1R) signaling axis drives a T-cell response toward transplantable tumor cells. Mouse NAIP1–6 proteins control phosphorylation of STAT3 and the expression of genes encoding antiapoptotic and proliferation-related molecules. NLRC4 controls the suppression of melanoma growth by amplifying inflammation in macrophages and potentiates production of IFNγ in T cells. AIM2 inhibits phosphorylation of AKT and cMyc activities and stem cell proliferation, while preventing colonization of colitogenic microbiota. B, The NLRP3–IL1β–IL1R signaling axis suppresses the tumoricidal activity of NK cells and T cells and promotes methylcholanthrene (MCA)-induced fibrosarcomas. It also induces secretion of IL17 by CD4+ T cells and dampens the antitumor efficacy of chemotherapeutic agents in thymoma. Overexpression of IL1β mobilizes myeloid-derived suppressor cells (MDSC) to the stomach and induces gastric cancer. IL1 signaling drives accumulation of MDSCs and promotes primary and metastatic mammary tumors. Inflammamome-independent activity of NLRP3 suppresses NK cells and increases lung metastasis in certain models of melanoma. The NLRC4 inflammasome mediates expression of adipocyte-mediated vascular endothelial growth factor A (VEGFA) and accelerates the progression of breast cancer. In some cases, ASC increases the viability and growth of melanoma
cells and promotes inflammation in infiltrating myeloid cells and the development of skin cancer. Mutations in the gene encoding NLRP1 are linked to melanoma and epidermal hyperplasia in humans.

9–11, 15–38). In contrast with previous studies showing that mice
lacking IL18 are susceptible to DSS-induced intestinal inflammation and tumorigenesis (9, 16, 17), a study has found that mice with a conditional deletion of IL18 in either epithelial cells or hematopoietic cells are more resistant to DSS-induced colitis compared with cohoused wild-type mice, indicating an IL18-dependent function in both enterocytes and hematopoietic cells (39). Under cohousing conditions whereby mice harbor a similar microbiota profile, IL18 inhibits goblet cell maturation prior to the onset of colitis to drive pathology (39). However, injection of recombinant IL18 into mice lacking inflammasome components reduces the prevalence of tumors in response to AOM and DSS (9), suggesting that this inflammasome-associated cytokine could be considered a potential candidate in immunotherapy against certain cases of colorectal cancer.

NLRP3 inflammasome-mediated secretion of IL18 can also induce tumoricidal activity of NK cells against metastasized colonic tumor cells in the mouse liver (19). In addition, IL18 promotes downregulation of the soluble IL22 receptor, IL22-binding protein (IL22BP; ref. 24; Fig. 1A). Controlled production of IL22BP fine-tunes the biological activity of IL22, a cytokine that exerts protective effects against intestinal damage at the peak of inflammation and promotes tumor development at later stages (24). IL22 also maintains IL18 expression in epithelial cells of the ileum, whereas IL18 itself is required for IL22 expression in CD4+ T cells and innate lymphoid cells (40).

The diametrical roles of IL18 have also been observed in lung metastasis. Recombinant IL18 injected into mice twice within a week enhances the development of B16F10 metastases, whereas daily administration for 5 days reduces tumorigenesis (41). In

©2017 American Association for Cancer Research

Published OnlineFirst January 16, 2017; DOI: 10.1158/2326-6066.CIR-16-0269

Figure 1.
Diverse roles of inflammasome sensors in tumorigenesis. A, NLRP1b, NLRP3, and NLRP6 mediate the production of IL18, contributing to the protection against colitis-associated colorectal cancer. The IL18 axis can also induce tumoricidal activity of NK cells against metastasized colonic tumor cells, downregulate IL22 binding protein (IL22BP), and inhibit the colonization of colitogenic microbiota, possibly through its role in MUC2 secretion by goblet cells. The NLRP3 inflammasome and the IL1β–IL1 receptor (IL1R) signaling axis drives a T-cell response toward transplantable tumor cells. Mouse NAIP1–6 proteins control phosphorylation of STAT3 and the expression of genes encoding antiapoptotic and proliferation-related molecules. NLRC4 controls the suppression of melanoma growth by amplifying inflammation in macrophages and potentiates production of IFNγ in T cells. AIM2 inhibits phosphorylation of AKT and cMyc activities and stem cell proliferation, while preventing colonization of colitogenic microbiota. B, The NLRP3–IL1β–IL1R signaling axis suppresses the tumoricidal activity of NK cells and T cells and promotes methylcholanthrene (MCA)-induced fibrosarcomas. It also induces secretion of IL17 by CD4+ T cells and dampens the antitumor efficacy of chemotherapeutic agents in thymoma. Overexpression of IL1β mobilizes myeloid-derived suppressor cells (MDSC) to the stomach and induces gastric cancer. IL1 signaling drives accumulation of MDSCs and promotes primary and metastatic mammary tumors. Inflammamome-independent activity of NLRP3 suppresses NK cells and increases lung metastasis in certain models of melanoma. The NLRC4 inflammasome mediates expression of adipocyte-mediated vascular endothelial growth factor A (VEGFA) and accelerates the progression of breast cancer. In some cases, ASC increases the viability and growth of melanoma cells and promotes inflammation in infiltrating myeloid cells and the development of skin cancer. Mutations in the gene encoding NLRP1 are linked to melanoma and epidermal hyperplasia in humans.
addition, mice lacking IL18 are more susceptible to B16-F10 tumor metastasis (28). It is possible to speculate that temporary exposure to IL18 might drive inflammation and accelerate metastasis, whereas a sustained circuit of IL18 might be fully required to enhance and shape antitumor immunosurveillance. Indeed, IL18 has the capacity to fine-tune the activation status of NK cells (28, 41). In cases in which IL18 is detrimental, the use of IL18 binding protein (IL18BP, a soluble protein that binds to IL18) to neutralize IL18 might be beneficial in the treatment of certain types of cancer (Fig. 2; refs. 3, 41–51).

The NLRP3 inflammasome is also required for anticancer adaptive immune responses. The release of ATP by dying tumor cells treated with chemotherapeutic agents activates the NLRP3 inflammasome and the IL1β–IL1 receptor (IL1R) signaling axis in dendritic cells (ref. 25; Fig. 1A). This pathway drives an effective CD8+ T-cell response toward transplantable tumor cells (25). As a result, oxaliplatin therapy of transplantable tumors in mice lacking the NLRP3 inflammasome is ineffective because IL1 production from dendritic cells is not induced, nor are CD8+ T cells primed (25).

In addition to NLRP3, other NLR sensors, including NLRP1b and NLRP6, mediate protection against tumorigenesis (18, 20–23, 52; Fig. 1A). In mice, the NLRP1b inflammasome provides protection against colon tumorigenesis, mediating secretion of both IL1β and IL18 in stromal cells of the colon (18). NLRP6 has several interrelated mechanistic functions by which it confers protection against colon tumorigenesis in mice. NLRP6 has been proposed to activate caspase-1 and drive IL18 production in the intestine in response to AOM and DSS treatment (20–22). The NLRP6–IL18 signaling axis prevents the colonization of pro-colitogenic bacterial species TM7 and those of the Prevotellaceae family (21). Furthermore, NLRP6 is essential for MUC2 secretion by goblet cells to clear potentially colitogenic bacteria (23, 26). NLRP6–dependent secretion of MUC2 in the intestinal epithelium have been shown to be dependent and independent of the gut microbiota and the mouse facilities housing the animals.

The ability of inflammasome sensors to provide protection against cancer does not always rely on the effector functions of caspase-1 and the cytokines processed by inflammasomes (Fig. 1A). Mouse NAIP1–6 proteins are components of the NLRC4 inflammasome and have been linked to the protection against AOM-DSS–induced colorectal cancer (27). The mechanism

**Figure 2.** Therapeutic targets of the inflammasome pathway. Recognition of pathogen-associated molecular patterns (PAMP) or danger-associated molecular patterns (DAMP) by inflammasome-initiating sensors leads to the activation of the inflammasome and initiation of pyroptosis and release of the bioactive form of IL1β and IL18. IL1β and IL18 engage in autocrine and paracrine signaling pathways via the IL1 receptor (IL1R) and IL18 receptor (IL18R), respectively. The inflammasome signaling pathway can be inhibited by pharmacologic inhibition of activation of the inflammasome (parthenolide, MCC950, glyburide, and BAY-11-7082), ASC oligomerization (CRID3), caspase-1 (thalidomide and belnacasan or VX-765), and IL1R (anakinra or kineret, and rilonacept or arcaysta), or neutralizing IL1β (canakinumab or ilaris) or IL18 (IL18 binding proteins or IL18BP).
driving this response is independent of the NLRC4 inflamma-
some, but relates to the ability of NAIP proteins to inhibit
hyperactivation of the transcription factor STAT3 and the
expression of genes encoding antiapoptotic and proliferation-
related molecules (27). Further, some evidence suggests that
adjuvant-based cancer immunotherapies targeting cytosolic
NAIP proteins and surface-associated TLR5 could be beneficial.
The NAIP proteins and TLR5 both recognize flagellin of certain
bacteria (3). Enforced expression of flagellin in tumor cell lines,
ensuring dual recognition by NAIP proteins and TLR5, induces
tumor cell clearance by innate immune cells and activation of
tumor-specific CD4+ and CD8+ T-cell responses in mice (53). These
findings suggest that recognition of tumor cells by the inflamma-
some and other innate immune sensors could lead to
desirable outcomes.

The role of NLRC4 itself in the AOM-DSS–induced tumor
model is unclear; a study suggests that NLRC4 prevents colorectal
tumorigenesis via inhibiting cellular proliferation and driving cell
death (14), whereas another found no role for NLRC4 (10).
NLRC4 can also amplify inflammatory signaling pathways in
macrophages independently of inflammasome assembly and
potentiates production of IL1β in CD4+ and CD8+ T cells to
dampen melanoma tumor growth in mice (29).

In addition to NLRs, the DNA-sensing inflammasome sensor
AIM2 can inhibit AOM-DSS–induced and spontaneous colorectal
tumorigenesis via an inflammasome-independent mechanism
(refs. 30, 31; Fig. 1A). AIM2 inhibits overt proliferation of intesti-
tinal stem cells and promotes cell death (30). Furthermore, AIM2
interacts with and limits the activation of DNA-dependent protein
kinase (DNA-PK) to reduce phosphorylation of AKT, which
controls cell proliferation (31). In addition, AIM2 expression
prevents colonization of colitogenic microbiota and reduces
susceptibility of mice to colorectal tumorigenesis (30). Overall,
substantial evidence suggests that inflammasome sensors have
tumor-suppressive roles in certain forms of cancer. These onco-
genic inhibitory activities are dependent on the ability of inflam-
some sensors to modulate cytokine production, engaging T-
cell activities, cellular proliferation, and maturation, and the
microbiota profile of the host (Fig. 1A).

Detrimental Roles of Inflammasomes in Cancer

Activation of the inflammasome leads to inflammatory
responses and, in some cases, suppression of antitumor immu-
nity (Fig. 1B). NLRP3 activity is associated with increased lung
metastasis when mice were injected intravenously, but not
subcutaneously, with B16-F10 melanoma cells or RM-1 prosta-
tate carcinoma cells (28, 32). In this case, mice lacking NLRP3
have a substantially reduced number of lung metastases com-
pared with wild-type mice, whereas mice lacking caspase-1 and
caspase-11 or IL1R have a similar number of lung metastases
compared with wild-type mice (28). The negative effect of
NLRP3 is also observed when mice are vaccinated with wild-
type dendritic cells pulsed with B16-F10 melanoma cell lysates
prior to injection with B16-F10 melanoma, such that a greater
proportion of vaccinated mice lacking NLRP3 survived com-
pared with that of vaccinated wild-type mice (32). The dele-
terious effect of NLRP3 in the melanoma model is owing to its
ability to suppress activation of NK cells that secrete IFNγ and
kill tumor cells (ref. 28; Fig. 1B).

The inflammasome adaptor protein ASC also appears to
have multiple biological activities that affect the outcome of
tumorigenesis (34). A knockdown of the gene encoding ASC
increases the viability and growth of primary melanoma cells,
whereas it reduces the viability and growth of metastatic
melanoma cells, when these cells were injected into nude
mice (34). Using cell-type–specific knockout mouse strains
lacking ASC in a chemically induced skin carcinogenesis
model, ASC was found to limit keratinocyte proliferation
and tumor formation, whereas it promotes inflammation in
infiltrating myeloid cells and the development of tumors
(ref. 35; Fig. 1B). These findings further highlight the cell-
type and tissue-specific roles for inflammasome components
in cancer.

In addition to IL18, activation of the inflammasome leads to
secretion of the inflammasome substrate IL1β. IL1β is involved in
the pathogenesis of spontaneous gastric cancer or Helicobacter
felis–induced gastric cancer (33). A transgenic mouse strain
engineered to overexpress human IL1β in the stomach is prone
to developing gastric cancer due to increased mobilization of
myeloid-derived suppressor cells (MDSC) to the stomach (33). A
deleterious role for IL1 signaling is also supported by the finding
that mice lacking IL1R have a delayed accumulation of MDSCs
and reduced primary and metastatic mammary tumors (36),
suggesting that inflammation driven by the IL1R signaling path-
way is detrimental (Fig. 1B).

The relationship between IL1R signaling and MDSCs in
cancer is further demonstrated in a study showing that activ-
ation of the NLRP3 inflammasome by chemotherapeutic
agents gemcitabine and 5-fluorouracil leads to IL1β produc-
tion in MDSCs (37). Production of IL1β by MDSCs induces
secretion of IL17 by CD4+ T cells and dampens the antitumor
efficacy of gemcitabine and 5-fluorouracil (37). The IL1β–IL1R
signaling axis activated by the NLRP3 inflammasome has an
adverse role in methylcholanthrene (MCA)-induced fibrosar-
comas (28). In this case, IL1β suppresses the tumoricidal
activity of NK cells and T cells (28). Moreover, IL1β produced
as a result of activation of the NLRC4 inflammasome mediates
expression of adipocyte-mediated vascular endothelial growth
factor A and angiogenesis, which accelerates the progression
of breast cancer (38). Gain-of-function mutations in the gene
encoding NLRP1 induce spontaneous inflammasome activa-
tion and IL1 production and drives epidermal hyperplasia in
humans (ref. 6; Fig. 1B).

Owing to the detrimental effects of the IL1R signaling path-
way, treatment of mice with IL1R antagonist IL1Ra enhances
the antitumor effect of gemcitabine and 5-fluorouracil (37). In
addition, neutralizing IL1β or IL1R at early stages of tumori-
genesis reduces the incidence of MCA-induced fibrosarcomas in
mice (28). Inhibitors of IL1 cytokines, such as Anakinra, have
been suggested for use in prophylaxis or treatment of multiple
myeloma (ref. 48; Fig. 2). Similarly, thalidomide, an immu-
nomodulator approved by the FDA can inhibit caspase-1 acti-
vation and is used for the treatment of malignant myeloma
(ref. 46; Fig. 2). Excessive inflammation induced by inflamma-
some activation and inflammasome substrates is a consistent
theme that seems to explain the detrimental effects of inflam-
masomes in multiple forms of cancer. The complex and dia-
metrical roles of inflammasome components in different forms
of cancer suggest that anticancer therapies must be tailored to
the specific cancer type and stage of disease.
Conclusions

In this review, we provided a brief overview of the biological importance of inflammasomes in different forms of cancer. Activation of inflammasome sensors is largely beneficial in colitis-associated colorectal cancer largely owing to the epithelial healing effects of the IL18 signaling pathway, regulation of cellular proliferation, maturation and cell death, and maintenance of a healthy gut microbiota. Identification of novel tumor-suppressive mechanisms of inflammasome sensors pushes the boundaries of the traditional roles of inflammasomes.

In other cases, inflammation triggered by inflammasomes and IL1 signaling leads to suppression of antitumor immunity conferred by NK cells and T cells that is detrimental to the development of fibrosarcoma, melanoma, gastric carcinoma, and lung metastasis. As a result, boosting or reducing the activity of inflammasomes or their effector molecules could be efficacious by tailoring therapy to specific types of cancer. Several small molecules, antagonists, and monoclonal antibodies are being developed against components of the inflammasome for use in therapies to control cancer (Fig. 2). However, inappropriate use of inflammasome modulatory therapies might lead to suppression of antitumor immunity and/or increased susceptibility to infection and the development of metabolic and autoimmune diseases.

Because inflammasome sensors regulate multiple signaling pathways beyond that of caspase-1, an understanding of which molecular mechanism is governed by inflammasome components in specific tumors is essential. The protumorigenic and antitumorigenic properties of inflammasomes are largely determined by the types of cells, tissues, and organs involved. The use of tissue- and cell-type–specific conditional deletion approaches in mice would fully reveal the complex functions of inflammasomes in the progression of cancer. The biological relationship between inflammasomes and cancer provides promising avenues with which to explore new anticancer therapies.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Authors’ Contributions

Conception and design: R. Karki, S.M. Man, T.-D. Kanneganti.

Writing, review, and/or revision of the manuscript: R. Karki, S.M. Man, T.-D. Kanneganti.

Grant Support

Work from our laboratory is supported by the US National Institutes of Health (AI101935, AI24446, AR056296 and CA163507 to T.-D. Kanneganti), the American Lebanese Syrian Associated Charities (to T.-D. Kanneganti), and the R.G. Menzies Early Career Fellowship from the National Health and Medical Research Council of Australia (to S.M. Man).

References


Because inflammasome sensors regulate multiple signaling pathways beyond that of caspase-1, an understanding of which molecular mechanism is governed by inflammasome components in specific tumors is essential. The protumorigenic and antitumorigenic properties of inflammasomes are largely determined by the types of cells, tissues, and organs involved. The use of tissue- and cell-type–specific conditional deletion approaches in mice would fully reveal the complex functions of inflammasomes in the progression of cancer. The biological relationship between inflammasomes and cancer provides promising avenues with which to explore new anticancer therapies.

Disclosure of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

Authors’ Contributions

Conception and design: R. Karki, S.M. Man, T.-D. Kanneganti.

Writing, review, and/or revision of the manuscript: R. Karki, S.M. Man, T.-D. Kanneganti.

Grant Support

Work from our laboratory is supported by the US National Institutes of Health (AI101935, AI24446, AR056296 and CA163507 to T.-D. Kanneganti), the American Lebanese Syrian Associated Charities (to T.-D. Kanneganti), and the R.G. Menzies Early Career Fellowship from the National Health and Medical Research Council of Australia (to S.M. Man).
Inflamasomes and Cancer


# Inflammasomes and Cancer

Rajendra Karki, Si Ming Man and Thirumala-Devi Kanneganti


<table>
<thead>
<tr>
<th>Updated version</th>
<th>Access the most recent version of this article at: doi:10.1158/2326-6066.CIR-16-0269</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Cited articles</th>
<th>This article cites 53 articles, 19 of which you can access for free at: <a href="http://cancerimmunolres.aacrjournals.org/content/5/2/94.full#ref-list-1">http://cancerimmunolres.aacrjournals.org/content/5/2/94.full#ref-list-1</a></th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Citing articles</th>
<th>This article has been cited by 5 HighWire-hosted articles. Access the articles at: <a href="http://cancerimmunolres.aacrjournals.org/content/5/2/94.full#related-urls">http://cancerimmunolres.aacrjournals.org/content/5/2/94.full#related-urls</a></th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>E-mail alerts</th>
<th>Sign up to receive free email-alerts related to this article or journal.</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Reprints and Subscriptions</th>
<th>To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at <a href="mailto:pubs@aacr.org">pubs@aacr.org</a>.</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Permissions</th>
<th>To request permission to re-use all or part of this article, use this link <a href="http://cancerimmunolres.aacrjournals.org/content/5/2/94">http://cancerimmunolres.aacrjournals.org/content/5/2/94</a>. Click on &quot;Request Permissions&quot; which will take you to the Copyright Clearance Center's (CCC) Rightslink site.</th>
</tr>
</thead>
</table>